Upload Avatar (500 x 500)
Mingqian Feng
Life Science
Huazhong Agricultural University
Hubei
Language: Chinese, English
Antibody
Engineering
Tumor
Immunotherapy
Hematological
Diseases
Acute
Liver
Failure
Bioartificial
Areas of Focus
- Antibody engineering and tumor immunotherapy
- Immunotherapy for hematological diseases
- Acute liver failure and bioartificial liver therapy
Work Experience
- 2000.7-2005.9 - Huazhong Agricultural University - Lecturer
- 2008.10-2013.11 - NIH, USA - Postdoctoral Researcher
- 2013.11-2015.12 - NIH, USA - Assistant Researcher
- 2015.12-present - Huazhong Agricultural University - Professor
Academic Background & Achievements
- 1993.9-1997.7 Bachelor: Northwest A&F University, Plant Genetics and Breeding
- 1997.9-2000.7 Master: Northwest A&F University, Biochemistry and Molecular Biology
- 2005.9-2008.7 PhD: Nanjing University, Biology
Publications
- A novel LAG3 neutralizing antibody improves cancer immunotherapy by dual inhibition of MHC-II and FGL1 ligand binding., Dianbao Zuo, Yuankui Zhu, Ke Wang, Youjia Qin, Yiyi Su, Sina Lan, Yunyi Li, Shuang Dong, Yinming Liang, Mingqian Feng, 2024
- Mesothelin CAR-T cells expressing tumor-targeted immunocytokine IL-12 yield durable efficacy and fewer side effects., Yuankui Zhu, Ke Wang, Linghe Yue, Dianbao Zuo, Junfeng Sheng, Sina Lan, Zilong Zhao, Shuang Dong, Sheng Hu, Chen Xin, Mingqian Feng, 2024
- Immunotherapy of Epstein-Barr virus (EBV) infection and EBV-associated hematological diseases with gp350/CD89-targeted bispecific antibody., Huixia He, Feifei Lei, Le Huang, Ke Wang, Yaxi Yang, Liu Chen, Yun Peng, Yinming Liang, Huabing Tan, Xiaoyan Wu, Mingqian Feng, 2023
- EGFRvⅢ-targeted immunotoxin combined with temozolomide and bispecific antibody for the eradication of established glioblastoma., Le Huang, Huixia He, Ke Wang, Xuqian Ma, Xin Chen, Wenxin Chen, Xuan Wang, Xiaobing Jiang, Mingqian Feng, 2022
- Highly potent immunotoxins targeting the N-lobe of GPC3 for immunotherapy of hepatocellular carcinoma., Jingwen Li, Lanxin Xiang, Qian Wang, Xuqian Ma, Xin Chen, Yuankui Zhu, Yaxi Yang, Le Huang, Huixia He, Lilei Xu, Xinjun Liang, Shuang Dong, Sheng Hu, Hanjie Li, Mingqian Feng, 2022
- Combination therapy of hepatocellular carcinoma by GPC3-targeted bispecific antibody and Irinotecan is potent in suppressing tumor growth in mice., Xin Chen, Yanmin Chen, Rong Liang, Lanxin Xiang, Jingwen Li, Yuankui Zhu, Huixia He, Le Huang, Dianbao Zuo, Weihang Li, Xinjun Liang, Shuang Dong, Sheng Hu, Mitchell Ho, Mingqian Feng, 2022
- Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth., Xin Chen, Norhan Amar, Yuankui Zhu, Chunguang Wang, Chunjiao Xia, Xiaoqing Yang, Dongde Wu, Mingqian Feng, 2020
- Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma., Feng M, Gao W, Wang R, Chen W, Man Y, Fig WD, Wang X, Dimitrov DS, and Ho M, 2013
